Alizarin, an Agonist of AHR Receptor, Enhances CYP1A1 Enzyme Activity and Induces Transcriptional Changes in Hepatoma Cells.
AHR pathway
CYP1A1 activity
HepG2 cells
alizarin
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
24
09
2023
revised:
25
10
2023
accepted:
26
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
The phytopigment alizarin was previously characterized as an anti-tumor drug owing to its antioxidant or antigenotoxic activities. However, the safety of alizarin is currently still under dispute. In this study, we explored the activity of alizarin in the AHR-CYP1A1 pathway and analyzed the transcriptional changes affected by alizarin using human hepatoma cell line HepG2-based assays. The results showed that alizarin decreased HepG2 cell viability in a dose-dependent manner, with IC
Identifiants
pubmed: 37959792
pii: molecules28217373
doi: 10.3390/molecules28217373
pmc: PMC10650112
pii:
doi:
Substances chimiques
Cytochrome P-450 CYP1A1
EC 1.14.14.1
alizarin
60MEW57T9G
Receptors, Aryl Hydrocarbon
0
CYP1A1 protein, human
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : the Advanced Talents Incubation Program of Hebei University
ID : 050001-521000981349
Références
Mol Cancer Res. 2013 Jul;11(7):780-92
pubmed: 23576571
Food Chem Toxicol. 2010 Jan;48(1):320-5
pubmed: 19852997
Anal Bioanal Chem. 2014 Apr;406(9-10):2467-75
pubmed: 24493334
Mutat Res. 2002 Oct 31;508(1-2):147-56
pubmed: 12379470
Environ Health Perspect. 2003 Dec;111(16):1877-82
pubmed: 14644660
Annu Rev Cancer Biol. 2019 Mar;3:457-478
pubmed: 30882047
BMC Cancer. 2009 Jun 16;9:187
pubmed: 19531241
Prog Lipid Res. 2017 Jul;67:38-57
pubmed: 28606467
Mutagenesis. 2016 Nov;31(6):687-693
pubmed: 27549112
Br J Cancer. 1999 Mar;79(9-10):1340-6
pubmed: 10188874
J Biosci Bioeng. 2009 Mar;107(3):296-300
pubmed: 19269596
J Histochem Cytochem. 1969 Feb;17(2):110-24
pubmed: 4179464
Mutat Res. 2006 Jun 16;605(1-2):22-9
pubmed: 16678474
Cancer Sci. 2009 Dec;100(12):2261-7
pubmed: 19793347
Biology (Basel). 2014 Oct 17;3(4):645-69
pubmed: 25329374
Pharmaceutics. 2022 May 12;14(5):
pubmed: 35631633
Int J Mol Sci. 2020 Dec 31;22(1):
pubmed: 33396563
J Appl Toxicol. 2021 Sep;41(9):1438-1445
pubmed: 33438235
Front Oncol. 2022 May 20;12:861281
pubmed: 35669436
Int J Biol Sci. 2022 Mar 28;18(7):2759-2774
pubmed: 35541911
Arch Biochem Biophys. 2007 Aug 15;464(2):207-12
pubmed: 17481570
Food Chem Toxicol. 2022 Mar;161:112851
pubmed: 35139434
Toxicol Lett. 2016 Nov 16;262:27-38
pubmed: 27633141
Arch Toxicol. 2022 Feb;96(2):511-524
pubmed: 34783865
Mutat Res. 2007 Jan 10;626(1-2):128-34
pubmed: 17137831
J Orthop Res. 2012 Sep;30(9):1486-92
pubmed: 22411621
Bull Environ Contam Toxicol. 2022 Aug;109(2):401-408
pubmed: 35441856
Mutagenesis. 2017 Jul 1;32(4):429-435
pubmed: 28431147
Comp Biochem Physiol C Toxicol Pharmacol. 2014 Aug;164:27-34
pubmed: 24768776
Biol Pharm Bull. 2003 Dec;26(12):1754-60
pubmed: 14646185